Testing effectiveness (Phase 2)Study completedNCT04704219
What this trial is testing
Pembrolizumab Plus Lenvatinib for First-line Advanced/Metastatic Non-clear Cell Renal Cell Carcinoma (1L nccRCC) (MK-3475-B61)
Who this might be right for
Renal Cell Carcinoma
Merck Sharp & Dohme LLC 160